1. Home
  2. INNV vs EYPT Comparison

INNV vs EYPT Comparison

Compare INNV & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo InnovAge Holding Corp.

INNV

InnovAge Holding Corp.

HOLD

Current Price

$10.79

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

EYPT

EyePoint Pharmaceuticals Inc.

HOLD

Current Price

$13.66

Market Cap

1.3B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
INNV
EYPT
Founded
2007
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Nursing Services
Biotechnology: Laboratory Analytical Instruments
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.3B
IPO Year
2021
2005

Fundamental Metrics

Financial Performance
Metric
INNV
EYPT
Price
$10.79
$13.66
Analyst Decision
Sell
Strong Buy
Analyst Count
1
5
Target Price
$7.00
$31.80
AVG Volume (30 Days)
346.4K
1.1M
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$853,699,000.00
$7,539,000.00
Revenue This Year
$12.85
N/A
Revenue Next Year
$8.88
$3,115.57
P/E Ratio
N/A
N/A
Revenue Growth
11.76
N/A
52 Week Low
$3.13
$8.96
52 Week High
$10.69
$19.11

Technical Indicators

Market Signals
Indicator
INNV
EYPT
Relative Strength Index (RSI) 80.18 54.50
Support Level $7.33 $13.61
Resistance Level $10.69 $14.82
Average True Range (ATR) 0.53 0.80
MACD 0.20 0.18
Stochastic Oscillator 90.90 64.85

Price Performance

Historical Comparison
INNV
EYPT

About INNV InnovAge Holding Corp.

InnovAge Holding Corp is a healthcare delivery platform comprising multiple participants focused on providing all-inclusive, capitated care to high-cost seniors, many of whom are dual-eligible. Its programs are designed to address two of the pressing challenges facing the U.S. healthcare industry: rising costs and poor outcomes. The purpose of the participant-centered care delivery approach is to improve the quality of care participants receive, while keeping them in their homes for as long as possible and reducing the overutilization of high-cost care settings, such as hospitals and nursing homes. The company manages its business as one reportable segment, PACE.

About EYPT EyePoint Pharmaceuticals Inc.

EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.

Share on Social Networks: